X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will be used to support the advancement of Bicara’s lead product, BCA101, a first-in-class bifunctional EGFR/TGF-β inhibitor, for multiple cancer types including frontline HPV-negative, R/M HNSCC, advanced squamous NSCLC and cutaneous squamous cell carcinoma.
Lead Product(s): BCA101,Pembrolizumab
Therapeutic Area: Oncology Product Name: BCA101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Braidwell LP
Deal Size: $165.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing December 12, 2023
Details:
The Financing will support future studies of lead program BCA101, a first-in-class EGFR / TGF-β-trap bifunctional antibody, currently in Phase 1/1b clinical development in head and neck cancer, and pipeline growth.
Lead Product(s): BCA101,Pembrolizumab
Therapeutic Area: Oncology Product Name: BCA101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Red Tree Venture Capital
Deal Size: $108.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 06, 2023
Details:
BCA356 specifically targets CAIX-expressing tumor cells, and similar to wild type IL-12 cytokine, has the potential to reduce tumor proliferation with optimal activation of additional pro-inflammatory cytokines.
Lead Product(s): BCA356
Therapeutic Area: Oncology Product Name: BCA356
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
BCA101 is a first-in-class antibody with a unique mechanism of anti-tumor activity that has demonstrated encouraging safety, pharmacokinetic, pharmacodynamic and efficacy profiles.
Lead Product(s): BCA101,Pembrolizumab
Therapeutic Area: Oncology Product Name: BCA101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2022
Details:
Study will evaluate BCA101, EGFR / TGF-β-trap bifunctional antibody in patients with head and neck squamous cell carcinoma, squamous cell carcinoma of the anal canal and cutaneous squamous cell carcinoma.
Lead Product(s): BCA101,Pembrolizumab
Therapeutic Area: Oncology Product Name: BCA101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2022
Details:
Bicara’s lead program, BCA101, a first-in-class EGFR / TGFβ-trap bifunctional antibody, entered a Phase 1/2 study at leading U.S. and Canadian cancer centers in July 2020.
Lead Product(s): BCA101
Therapeutic Area: Oncology Product Name: BCA101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biocon
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
